Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
Show more...
FAQ
Target Healthcare REIT 今天的股價是多少?▼
37Z.F 目前價格為 €1.16 EUR,過去 24 小時上漲了 +0.87%。在圖表上更密切關注 Target Healthcare REIT 股價表現。
Target Healthcare REIT 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Target Healthcare REIT 的股票以代號 37Z.F 進行交易。
Target Healthcare REIT 去年的營收是多少?▼
Target Healthcare REIT 去年的營收為 0EUR。
Target Healthcare REIT 去年的淨利是多少?▼
37Z.F 去年的淨收益為 -106.94MEUR。
Target Healthcare REIT 會發放股息嗎?▼
是的,37Z.F 的股息每 每季 發放一次。每股最新股息為 0.02 EUR。截至今日,股息殖利率(FWD)% 為 5.97%。
Target Healthcare REIT 有多少名員工?▼
截至 May 26, 2026,公司共有 167 名員工。
Target Healthcare REIT 位於哪個產業?▼
Target Healthcare REIT從事於Health & Wellness產業。
Target Healthcare REIT 何時完成拆股?▼
Target Healthcare REIT 最近沒有進行任何拆股。